KBI Biopharma and Selexis, announced today that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Swi...
Womack will be responsible for the strategic vision, continued growth, and organizational culture of both organizations, which currently includes eight facilities in Europe and the US.
KBI, a JSR Life Sciences company, held a ribbon-cutting at the company’s new state-of-the-art $150 million, 150,000 square-foot commercial manufacturing facility in Research Triangle Park...
The clinical resupply services will be delivered under AdAlta’s contract development and manufacturing Master Services Agreement with KBI Biopharma that was announced on 5 June 2018.
Selexis and KBI announced today that they have signed service agreements with Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redire...
